Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo

Pharmaceutical Research

Volumn 29, Issue 5, 2012, Pages 1203-1218

  Sapet, Cédric ^a   Pellegrino, Christophe ^b   Laurent, Nicolas ^a   Sicard, Flavie ^a   Zelphati, Olivier ^a  

^a OZ Biosciences   (France)

^b Turing Center for Living Systems CENTURI Aix Marseille University   (France)

Author keywords

AdenoMag; Adenovirus; In vivo transduction; Magnetic cell sorting; Magnetofection

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; GREEN FLUORESCENT PROTEIN; MAGNETIC NANOPARTICLE;

ADENOVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LINE; CELL SELECTION; CELL SEPARATION; CONTROLLED STUDY; DNA MODIFICATION; DOSE RESPONSE; EMBRYO; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; GENE TECHNOLOGY; GENETIC TRANSFECTION; HARD TO INFECT CELL LINE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; INTEGRATED MAGNETIC IMMUNO CELL SORTING AND TRANSDUCTION; MAGNETIC FIELD; MAGNETOFECTION; MEDICAL TECHNOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HELA CELLS; HUMANS; MAGNETICS; RATS; RATS, WISTAR; TIME FACTORS; TRANSDUCTION, GENETIC;

EID: 84862646022     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0629-9     Document Type: Article

References (74)

1. Davison AJ, Benko M, Harrach B. Genetic content and evolution of adenoviruses. J Gen Virol. 2003;84(Pt 11):2895-908.
2. Zhang WW. Development and application of adenoviral vectors for gene therapy of cancer. Canc Gene Ther. 1999;6(2):113-38.
3. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther. 2003;8(5):846-52.
4. Russell WC. Update on adenovirus and its vectors. J Gen Virol. 2000;81(Pt 11):2573-604.
5. Pandori M, Hobson D, Sano T. Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery. Virology. 2002;299(2):204-12.
6. Nyanguile O, Dancik C, Blakemore J, Mulgrew K, Kaleko M, Stevenson SC. Synthesis of adenoviral targeting molecules by intein-mediated protein ligation. Gene Ther. 2003;10(16):1362-9.
7. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther. 2001;3 (5 Pt 1):708-22.
8. Parker AL, Nicklin SA, Baker AH. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Curr Opin Mol Ther. 2008;10(5):439-48.
9. Fechner H, Haack A, Wang H, Wang X, Eizema K, Pauschinger M, et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 1999;6 (9):1520-35.
10. Bergelson JM. Receptors mediating adenovirus attachment and internalization. Biochem Pharmacol. 1999;57(9):975-9.
11. Leopold PL, Crystal RG. Intracellular trafficking of adenovirus: manymeans tomany ends. Adv Drug Deliv Rev. 2007;59(8):810-21.
12. Xu ZL, Mizuguchi H, Sakurai F, Koizumi N, Hosono T, Kawabata K, et al. Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev. 2005;57(5):781-802.
13. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther. 2004;15(1):35-46.
14. Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trapnell BC. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther. 1994;5(6):731-44.
15. Thomas CE, Birkett D, Anozie I, Castro MG, Lowenstein PR. Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther. 2001;3(1):36-46.
16. Heise CC, Williams AM, Xue S, Propst M, Kirn DH. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 1999;59(11):2623-8.
17. Curiel DT. Rational design of viral vectors based on rigorous analysis of capsid structures. Mol Ther. 2000;1(1):3-4.
18. Krasnykh VN, Douglas JT, van Beusechem VW. Genetic targeting of adenoviral vectors. Mol Ther. 2000;1(5 Pt 1):391-405.
19. Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Kruger A, et al. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 2002;9 (2):102-9.
20. Plank C, Zelphati O, Mykhaylyk O. Magnetically enhanced nucleic acid delivery. Ten years of magnetofection-Progress and prospects. Adv Drug Deliv Rev. 2011.
21. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010;463 (7281):676-80.
22. Sacha JB, Reynolds MR, Buechler MB, Chung C, Jonas AK, Wallace LT, et al. Differential antigen presentation kinetics of CD8+ T-cell epitopes derived from the same viral protein. J Virol. 2008;82(18):9293-8.
23. Orlando C, Castellani S, Mykhaylyk O, Copreni E, Zelphati O, Plank C, et al. Magnetically guided lentiviral-mediated transduction of airway epithelial cells. J Gene Med. 2010;12(9):747-54.
24. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, Chung C, et al. Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci U S A. 2009;106 (24):9791-6.
25. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, et al. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol;84 (20):10543-57.
26. Kadota S, Kanayama T, Miyajima N, Takeuchi K, Nagata K. Enhancing of measles virus infection by magnetofection. J Virol Meth. 2005;128(1-2):61-6.
27. Satoh S, Masatoshi S, Shou Z, Yamamoto T, Ishigure T, Semii A, et al. Identification of cis-regulatory elements and trans-acting proteins of the rat carbohydrate response element binding protein gene. Arch Biochem Biophys. 2007;461(1):113-22.
28. Satoh K, Iwata A, Murata M, Hikata M, Hayakawa T, Yamaguchi T.Virus concentration using polyethyleneimine-conjugatedmagnetic beads for improving the sensitivity of nucleic acid amplification tests. J Virol Meth. 2003;114(1):11-9.
29. Schyth BD, Lorenzen N, Pedersen FS. A high throughput in vivo model for testing delivery and antiviral effects of siRNAs in vertebrates. Mol Ther. 2007;15(7):1366-72.
30. Raty JK, Airenne KJ, Marttila AT, Marjomaki V, Hytonen VP, Lehtolainen P, et al. Enhanced gene delivery by avidin-displaying baculovirus. Mol Ther. 2004;9(2):282-91.
31. Grard G, Moureau G, Charrel RN, Lemasson JJ, Gonzalez JP, Gallian P, et al. Genetic characterization of tick-borne flaviviruses: new insights into evolution, pathogenetic determinants and taxonomy. Virology. 2007;361(1):80-92.
32. Mah C, Fraites Jr TJ, Zolotukhin I, Song S, Flotte TR, Dobson J, et al. Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol Ther. 2002;6(1):106-12.
33. Chorny M, Fishbein I, Alferiev I, Levy RJ. Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells. Mol Pharm. 2009;6 (5):1380-7.
34. Hashimoto M, Hisano Y. Directional gene-transfer into the brain by an adenoviral vector tagged with magnetic nanoparticles. J Neurosci Meth. 2011;194(2):316-20.
35. Bhattarai SR, Kim SY, Jang KY, Lee KC, Yi HK, Lee DY, et al. Laboratory formulated magnetic nanoparticles for enhancement of viral gene expression in suspension cell line. J Virol Meth. 2008;147(2):213-8.
36. Laurent N, Sapet C, Le Gourrierec L, Bertosio E, Zelphati O. Nucleic acid delivery using magnetic nanoparticles: the Magnetofection™ technology. Ther Deliv. 2011;2(4):471-82.
37. Tresilwised N, Pithayanukul P, Mykhaylyk O, Holm PS, Holzmuller R, Anton M, et al. Boosting oncolytic adenovirus potency with magnetic nanoparticles and magnetic force. Mol Pharm. 2010;7 (4):1069-89.
38. Sapet C, Laurent N, Le Gourrierec L, Augier S, Zelphati O. In vitro and in vivo Magnetofection: a move towards gene therapy. Ann Biol Clin (Paris). 2010;68(2):133-42.
39. Sanchez-Antequera Y, Mykhaylyk O, van Til NP, Cengizeroglu A, de Jong JH, Huston MW, et al. Magselectofection: an integrated method of nanomagnetic separation and genetic modification of target cells. Blood. 2011;117(16):e171- 81.
40. Mathis JM, Stewart PL, Zhu ZB, Curiel DT. Advanced generation adenoviral virotherapy agents embody enhanced potency based upon CAR-independent tropism. Clin Cancer Res. 2006;12 (9):2651-6.
41. Buerli T, Pellegrino C, Baer K, Lardi-Studler B, Chudotvorova I, Fritschy JM, et al. Efficient transfection of DNA or shRNA vectors into neurons using magnetofection. Nat Protoc. 2007;2 (12):3090-101.
42. Arcasoy SM, Latoche JD, Gondor M, Pitt BR, Pilewski JM. Polycations increase the efficiency of adenovirus-mediated gene transfer to epithelial and endothelial cells in vitro. Gene Ther. 1997;4(1):32-8.
43. Peixoto C, Ferreira TB, Sousa MF, Carrondo MJ, Alves PM. Towards purification of adenoviral vectors based on membrane technology. Biotechnol Prog. 2008;24(6):1290-6.
44. Sacha JB, Watkins DI. Synchronous infection of SIV and HIV in vitro for virology, immunology and vaccine-related studies. Nat Protoc. 2010;5(2):239-46.
45. Preuss MA, Glasgow JN, Everts M, Stoff-Khalili MA, Wu H, Curiel DT. Enhanced gene delivery to human primary endothelial cells using tropism-modified adenovirus vectors. Open Gene Ther J. 2008;1:7-11.
46. Bowers WJ, Breakefield XO, Sena-Esteves M. Genetic therapy for the nervous system. Hum Mol Genet;20(R1):R28-41.
47. Plank C, Anton M, Rudolph C, Rosenecker J, Krotz F. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Ther. 2003;3(5):745-58.
48. Ziello JE, Huang Y, Jovin IS. Cellular endocytosis and gene delivery. Mol Med. 2010;16(5-6):222-9.
49. Mohler 3rd ER, Rajagopalan S, Olin JW, Trachtenberg JD, Rasmussen H, Pak R, et al. Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial. Vasc Med. 2003;8(1):9-13.
50. Rajagopalan S, Mohler 3rd ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108(16):1933-8.
51. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)- CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther. 2003;14(11):1079-88.
52. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum Gene Ther. 2005;16(5):541-50.
53. Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113(9):1909-18.
54. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol. 2005;79(12):7478-91.
55. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132(3):397-409.
56. Smith JS, Xu Z, Tian J, Stevenson SC, Byrnes AP. Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum Gene Ther. 2008;19(5):547-54.
57. Prill JM, Espenlaub S, Samen U, Engler T, Schmidt E, Vetrini F, et al. Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther. 2010;19(1):83-92.
58. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther. 2005;11(1):66-79.
59. Jahnke A, Hirschberger J, Fischer C, Brill T, Kostlin R, Plank C, et al. Intra-tumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: a phase-I study. J Vet Med A Physiol Pathol Clin Med. 2007;54(10):599-606.
60. Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol. 2007;2(8):495-9.
61. Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs. 2009;23(1):35-58.
62. Saito T, Nakatsuji N. Efficient gene transfer into the embryonic mouse brain using in vivo electroporation. Dev Biol. 2001;240 (1):237-46.
63. Takahashi M, Sato K, Nomura T, Osumi N. Manipulating gene expressions by electroporation in the developing brain of mammalian embryos. Differentiation. 2002;70(4-5):155-62.
64. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2009;27(1):59-65.
65. Minang JT, Trivett MT, Barsov EV, Del Prete GQ, Trubey CM, Thomas JA, et al. TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection. Virology 2011.
66. Greene JM, Lhost JJ, Burwitz BJ, Budde ML, Macnair CE, Weiker MK, et al. Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo. J Virol. 2010;84 (7):3362-72.
67. Sacha JB, Buechler MB, Newman LP, Reed J, Wallace LT, Loffredo JT, et al. Simian immunodeficiency virus-specific CD8+ T cells recognize Vpr- and Rev-derived epitopes early after infection. J Virol. 2010;84(20):10907-12.
68. Berro R, Sanders RW, Lu M, Klasse PJ, Moore JP. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry. PLoS Pathog. 2009;5(8):e1000548.
69. Payne RP, Kloverpris H, Sacha JB, Brumme Z, Brumme C, Buus S, et al. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. J Virol. 2010;84 (20):10543-57.
70. Mizuhara E, Minaki Y, Nakatani T, Kumai M, Inoue T, Muguruma K, et al. Purkinje cells originate from cerebellar ventricular zone progenitors positive for Neph3 and E-cadherin. Dev Biol. 2010;338(2):202-14.
71. Nakatani T, Kumai M, Mizuhara E, Minaki Y, Ono Y. Lmx1a and Lmx1b cooperate with Foxa2 to coordinate the specification of dopaminergic neurons and control of floor plate cell differentiation in the developing mesencephalon. Dev Biol. 2010;339(1):101-13.
72. Wang X, Mani P, Sarkar DP, Roy-Chowdhury N, Roy- Chowdhury J. Ex vivo gene transfer into hepatocytes. Methods Mol Biol. 2009;481:117-40.
73. Burdorf L, Schuhmann N, Postrach J, Thein E, Hallek M, Reichart B, et al. AAV-mediated gene transfer to cardiac cells in a heterotopic rat heart transplantation model. Transplant Proc. 2007;39 (2):567-8.
74. Hofmann A, Wenzel D, Becher UM, Freitag DF, Klein AM, Eberbeck D, et al. Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc Natl Acad Sci U S A. 2009;106(1):44-9.